<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03114683</url>
  </required_header>
  <id_info>
    <org_study_id>CIBI308B201</org_study_id>
    <nct_id>NCT03114683</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety Evaluation of IBI308 in Treatment of Patients With Relapsed/Refractory Classical Hodgkin's Lymphoma: a Multicenter, Single Arm, Phase II Study</brief_title>
  <acronym>ORIENT-1</acronym>
  <official_title>Efficacy and Safety Evaluation of IBI308 in Treatment of Patients With Relapsed/Refractory Classical Hodgkin's Lymphoma: a Multicenter, Single Arm, Phase II Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Innovent Biologics (Suzhou) Co. Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Innovent Biologics (Suzhou) Co. Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study is to evaluate ORR, CR, PR DCR DOR PFS and safety of IBI308 in treatment of
      patients with Relaspsed/Refractory Hodgkin's Lymphoma.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">April 30, 2017</start_date>
  <completion_date type="Anticipated">April 30, 2019</completion_date>
  <primary_completion_date type="Anticipated">December 30, 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Objective Response Rate</measure>
    <time_frame>average 1 year</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Relapsed/Refractory Classical Hodgkin's Lymphoma</condition>
  <arm_group>
    <arm_group_label>IBI308</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PD1</intervention_name>
    <description>IBI308 200mg/3 weeks</description>
    <arm_group_label>IBI308</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Histopathological confirmed classical Hodgkin's lymphoma (cHL).

          2. Relapsed/refractory cHL, which failed second line and above therapy (including
             radiotherapy and autologous hematopoietic stem cell transplantation, ASCT); subject
             with no response to or with progression after ASCT is eligible.

          3. At least one measurable disease (long axis&gt;15 mm or short axis&gt;10 mm, with uptake on
             18FDG-PET)

          4. Eastern Cooperative Oncology Group Performance Status (ECOG PS) 0-2.

          5. Signed written informed consent form and willing and able to comply with scheduled
             visits and other requirements of the study.

          6. Age ≥ 18.

          7. Life expectancy of at least 12 weeks.

          8. Subjects of reproductive potential must be willing to use adequate contraception
             during the course of the study and through 90 days after the last dose of study
             medication.

          9. Adequate organ and bone marrow function:

               1. Count of Blood Cells: absolute neutrophil count (ANC) ≥ 0.75 × 109 / L; platelet
                  count (PLT) ≥ 50 × 109 / L; hemoglobin content (HGB) ≥ 8.0 g / Dl; no granulocyte
                  colony-stimulating factor, platelet or red blood cells infusion in the last 14
                  days.

               2. Liver function: serum total bilirubin (TBIL) ≤ 1.5 × normal upper limit (ULN);
                  alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 2.5 × ULN.

               3. Renal function: serum creatinine (Cr) ≤ 1.5 × ULN

               4. Thyroid function: thyroid stimulating hormone (TSH) in normal range.

        Exclusion Criteria:

          1. Known nodular lymphocyte predominant Hodgkin lymphoma.

          2. Known central nervous system lymphoma.

          3. Received ASCT within 90 days of the first dose of study medication.

          4. Prior exposure to any anti-PD-1, anti-PD-L1 or anti-CTLA-4 antibody.

          5. Currently participating in an interventional clinical study, unless participating in
             observational study or during follow-up period of an interventional study.

          6. Received any investigational agent within 4 weeks of the first dose of study
             medication.

          7. Received last dose of radiotherapy or anti-tumor therapy (chemotherapy, targeted
             therapy, tumor immunotherapy or arterial embolization) within 3 weeks of the first
             dose of study medication; received last dose of nitrosourea or mitomycin C within 6
             weeks of the first dose of study medication.

          8. Received systemic treatment with corticosteroids (&gt; 10 mg daily prednisone equivalent)
             or other immunosuppressive medications within 4 weeks of first dose. Inhaled or
             topical steroids and adrenal replacement steroid doses are permitted in the absence of
             active autoimmune disease.

          9. Received a live vaccine within 4 weeks of the first dose of study medication or plan
             to receive live vaccine during study period.

         10. Underwent major operation (craniotomy, thoracotomy or laparotomy) within 4 weeks of
             the first dose of study medication or open wound, ulcer or fracture.

         11. Unrecovered toxicity (grade &gt;1, according to NCI CTCAE 4.03) due to prior anti-tumor
             therapy before the first dose of study medication.

         12. Active, known or suspected autoimmune disease or has a history of the disease within
             the last 2 years (subjects with vitiligo, psoriasis, alopecia or Grave's disease,
             residual hypothyroidism due to autoimmune thyroiditis only requiring hormone
             replacement, or type I diabetes mellitus only requiring insulin replacement, but not
             required systemic treatment in the last 2 years, are permitted to enroll).

         13. Known primary immunodeficiency.

         14. Active tuberculosis.

         15. Known history of allogeneic organ or allogeneic hemopoietic stem cell transplantation.

         16. Known allergy or hypersensitivity to any monoclonal antibodies or any components used
             in their preparation.

         17. Uncontrolled concomitant disease, including but not limited to :

               1. Human Immunodeficiency Virus (HIV) infection (HIV antibody positive)

               2. Active or poorly controlled severe infection

               3. Symptomatic congestive heart failure (New York Heart Association grade II-IV) or
                  symptomatic, poorly controlled arrhythmia

               4. Poorly controlled arterial hypertension (SBP ≥ 160mmHg or DBP ≥ 100mmHg) with
                  standard treatment

               5. Prior arterial thromboembolism event, including myocardial infarction, unstable
                  angina, stroke and transient ischemic attack, within 6 months of enrollment

               6. Prior life-threatening blood loss or grade 3/4 gastrointestinal/varicosity
                  bleeding requiring blood infusion, endoscopic or surgical intervention within 3
                  months of enrollment

               7. Prior deep vein thrombosis, pulmonary embolism or any other severe
                  thromboembolism events (implanted port or catheter caused thrombosis, or
                  superficial vein thrombosis are not considered as severe thromboembolism) within
                  3 months before enrollment

               8. History of uncontrolled metabolic disorder, non-malignant organ or systemic
                  disease or secondary carcinomatous reaction, with high medical risk and/or
                  uncertainty of life expectancy evaluation

               9. With hepatic encephalopathy, hepatorenal syndrome or hepatic cirrhosis of
                  Child-Pugh grade B or higher.

              10. History of intestinal obstruction or the following diseases: inflammatory bowel
                  disease or extensive bowel resection (partial colonic resection or extensive
                  small bowel resection, concomitant with chronic diarrhea), Crohn's disease,
                  ulcerative colitis or chronic diarrhea

              11. Other acute or chronic diseases, mental illness, or abnormal laboratory test
                  results that may lead to the following outcomes: increase the risk of
                  participating in study or study drug administration, or interfere with the
                  interpretation of the study results and considered by investigator as &quot;NOT&quot;
                  eligible to participate in this study

         18. Known acute or chronic active hepatitis B infection (chronic HBV carrier or non-active
             HBsAg positive subject is eligible) or acute or chronic active hepatitis C (HCV
             antibody negative subject is eligible; HCV RNA examination is required for HCV
             antibody positive subject, subject is eligible if result was negative)

         19. History of gastrointestinal perforation and /or fistula within 6 months before
             enrollment

         20. Subjects with a history of interstitial lung disease

         21. Uncontrolled third space effusion, eg. ascites or pleural effusion cannot be drained
             or controlled

         22. Other primary malignancy, with the exception of:

               1. Curative malignancy, without active disease in the last 5 years and with very low
                  recurrence risk

               2. Non-melanoma skin cancer or malignant freckle-like nevus with adequate treatment
                  and no evidence of recurrence ;

               3. Adequately treated in-situ carcinoma

         23. Women who are pregnant or nursing.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>April 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 4, 2017</study_first_submitted>
  <study_first_submitted_qc>April 10, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">April 14, 2017</study_first_posted>
  <last_update_submitted>April 10, 2017</last_update_submitted>
  <last_update_submitted_qc>April 10, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 14, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Hodgkin Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

